- Home
- LPTX vs VGI Comparison
LPTX vs VGI Comparison
Compare LPTX & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- VGI
- Stock Information
- Founded
- LPTX 2011
- VGI 2012
- Country
- LPTX United States
- VGI United States
- Employees
- LPTX N/A
- VGI N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- VGI Investment Managers
- Sector
- LPTX Health Care
- VGI Finance
- Exchange
- LPTX Nasdaq
- VGI Nasdaq
- Market Cap
- LPTX 11.1M
- VGI 89.7M
- IPO Year
- LPTX N/A
- VGI N/A
- Fundamental
- Price
- LPTX $0.32
- VGI $7.98
- Analyst Decision
- LPTX Hold
- VGI
- Analyst Count
- LPTX 1
- VGI 0
- Target Price
- LPTX N/A
- VGI N/A
- AVG Volume (30 Days)
- LPTX 685.3K
- VGI 46.0K
- Earning Date
- LPTX 11-12-2025
- VGI 01-01-0001
- Dividend Yield
- LPTX N/A
- VGI 12.66%
- EPS Growth
- LPTX N/A
- VGI N/A
- EPS
- LPTX N/A
- VGI N/A
- Revenue
- LPTX N/A
- VGI N/A
- Revenue This Year
- LPTX N/A
- VGI N/A
- Revenue Next Year
- LPTX N/A
- VGI N/A
- P/E Ratio
- LPTX N/A
- VGI N/A
- Revenue Growth
- LPTX N/A
- VGI N/A
- 52 Week Low
- LPTX $0.22
- VGI $6.68
- 52 Week High
- LPTX $4.79
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- LPTX 58.29
- VGI 50.10
- Support Level
- LPTX $0.28
- VGI $7.96
- Resistance Level
- LPTX $0.29
- VGI $8.04
- Average True Range (ATR)
- LPTX 0.02
- VGI 0.05
- MACD
- LPTX 0.01
- VGI -0.01
- Stochastic Oscillator
- LPTX 92.61
- VGI 15.38
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.